An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Cholbam

Chemical Namecholic acid
Dosage FormCapsule (oral; 50 mg, 250 mg)
Drug ClassEnzymes
SystemDigestive
CompanyPatheon France SA
Approval Year2015

Indication

  • Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs).
  • Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat soluble vitamin absorption.
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cholbam (cholic acid) Prescribing Information 2017Manchester Pharmaceuticals, Inc. a wholly owned subsidiary of Retrophin, Inc., San Diego, CA
Document TitleYearSource
An open label, single center, nonrandomized continuation study of cholic acid capsules to treat subjects with inborn errors of bile acid synthesis. 2020Retrophin, Inc.
Oral cholic acid is efficacious and well tolerated in patients with bile acid synthesis and Zellweger spectrum disorders. 2017Journal of Pediatric Gastroenterology and Nutrition